Skip to main content

Real-World Data


Richard Lee-Ying, MD, discusses clinical outcomes of patients with metastatic castrate resistant prostate cancer when Ra-223 is used early vs late in the treatment sequence.
Akram Mesleh Shayeb, MD, discusses results from a real-world study evaluating cabozantinib in combination with direct…
Conference Coverage
Study results show that immunotherapy is the most common next line of therapy after discontinuation of an EGFR-TKI and…
A recent real-world study compared HCRU and costs associated with first-line ibrutinib monotherapy vs bendamustine plus…
Conference Coverage
Treatment guided by biomarker testing is associated with improved survival outcomes in patients with advanced or…
Back to Top